London‑based venture firm Medicxi raised €500 million for Fund V to finance asset‑centric biotech startups and selective later‑stage opportunities. The oversubscribed fund continues Medicxi’s strategy of launching focused companies built around single assets and follows a track record of exits and licensing deals across vaccines and specialty therapeutics. The raise signals persistent VC interest in concentrated, milestone‑driven plays despite broader market turbulence.